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Nursing Care
Amyotrophic Lateral Sclerosis
Emily C. Stitzel, RN, BSN
Signs and Symptoms Underlying Pathophysiology References
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ALS identification is through the upper and lower motor neuron degeneration 
and death, by which there is axonal loss and myelin sheath damage (Rossie, Franco, 
& Estevez, 2013, pg. 2).   The effects of this disease are in the ventral horn and 
brainstem motor neurons through microglial activation and active macrophages 
(Rossie et al., 2013, pg. 2).   Also, the disease is increasingly thought to be a disorder 
of the RNA metabolism (Doppelmann et al., 2013, pg. 445).  Genetic basis of ALS is 
not known; however, frequently autosomal dominant transmission is shown, 
although there are instances where autosomal recessive pedigrees are seen (Wingo, 
Cutler, Yarab, Kelly, & Glass, 2011, pg. 1).  The heritability of ALS is estimated to be 
76% with the familial form (Wingo et al., 2011, pg. 1).  The actual gene that causes 
this process to happen within the body has been evasive throughout research.  Both 
sporadic and familial ALS have some commonalities, but not every diagnosis 
provides the same genetic makeup.  Currently, one of the most common mutations 
thought to cause ALS is on the Cu/Zn superoxide dismutase gene (SOD1), which 
counts for roughly 20% of familial ALS and 1% of spontaneous ALS cases 
(Droppelmann et al., 2013, pg. 444).  There has also been a discovery on a large 
repeat expansion in the C9ORF72 gene that accounts for 40% of familial cases of ALS 
in European and North American populations (Pliner, Mann, & Traynor, 2014, pg. 
391).  Although the genetic makeup of ALS has not fully been discovered, advances 
in research are leading to more knowledge as time continues.
• Due to the complexity, constant research must 
continue to be conducted
• Research should focus on finding the genetic 
mutations, causes, and eventually a way to 
avoid or cure the disease
• Presentation of signs and symptoms is 
important to diagnosis, and ruling out other 
mimic diseases is vital to diagnosis
• A caring and trusting attitude from the primary 
care provider is important to establish rapport.  
• During early stages of disease, quality of life for 
the individual should be discussed for future 
plans, including palliative measures
Characterization of the disease is the 
progression of upper and lower motor 
neuron degeneration.  The first signs and 
symptoms begin in either the limbs or 
bulbar muscles, and then spread 
(Gordon, 2013, pg. 296).  The loss of 
lower motor neuron (LMN) facilitates 
“fasciculation, cramps, muscle atrophy, 
and marked weakness” while the upper 
motor neuron (UMN) loss causes 
spasticity, hyperreflexia, and weakness 
(Gordon, 2013, pg 296).  Mimics of these 
signs include autoimmune motor 
neuropathy, spinal muscular atrophy, 
Kennedy’s disease, multiple sclerosis, 
and cervical myelopathy, as well as 
several others (Lawton et al., 2014, pg. 
363).  ALS symptoms generally start in 
the arms, mostly unilaterally and focal 
such as weakness when lifting arms or 
loss of hand dexterity (Gordon, 2013, pg. 
296).  Bulbar-onset carries a worse 
prognosis compared to limb onset; first 
symptoms include dysarthria followed by 
dysphagia which progresses to 
sialorrhea, malnutrition, and anarthria 
and a sure diagnosis includes atrophied 
fasciculating tongue (Gordon, 2013, pg. 
296).  As the diagnosis progresses, 
eventually respiratory failure will 
develop, and the patient may choose to 
be put on a ventilator, or may opt out and 
go into hospice as respiratory failure 
advances.  Electromyography confirms 
disease of LMN while ruling out the 
mimics, a brain and spinal MRI rule out 
conditions that could mimic UMN 
diseases, and occasionally the MRI will 
show bilateral signal changes within the 
corticospinal tract which is 
pathognomonic of ALS (Gordon, 2013, 
pg. 296).
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Conclusion
Amyotrophic Lateral Sclerosis (ALS) is a terminal neurodegenerative disorder 
affecting an individual’s motor neurons.  With a prevalence affecting an estimated 
20,000 to 30,000 people in the United States of America, the progressive disease 
affects the lives of many (Bellomo & Cichminski, 2015, pg. 47).  Highest rates are in 
white males, age 60-69 (Prevalence, 2015, pg. 7).  Survival rates range from a median 
of 37 to 49 months once the patient is diagnosed, showing this is a quick progressing 
disease that will lead to fatality (Malik, Lui, & Lomen-Hoerth, 2014, pg. 534).  The 
patients affected by the disease normally present with asymmetric, painless weakness 
and possibly impaired speech or swallowing, spasticity, bradykinesia, pathological 
hyperreflexia, and Babinski signs (Malik et al., 2014, pg. 534).  As the disease 
progresses, patients will require braces, canes, walkers, and eventually wheelchairs 
(Malik et al., 2014, pg. 535-536).  The genetic basis of ALS is undetermined, however 
there is familial clustering that can suggest a genetic foundation (Wingo, Cutler, Yarab, 
Kelly, & Glass, 2011, pg. 1).  With such uncertainty about the mechanisms of this 
disease, research is consistently being performed for more information.  
Why Amyotrophic Lateral Sclerosis Matters
As a neurological nurse, the mystery behind ALS has always been fascinating.  
The mechanisms in which the body deteriorates, the cognitive function of the 
individual suffering from the disease, and the inability to determine the exact cause 
has stumbled science for years.  As someone who sees the effects at the hospital 
bedside and the toll the disease has on the patients and their loved ones, an 
importance has always been prominent.  With such complexity within ALS, interest 
could only be procured from this disease.
Interest
• Be supportive
• Promote open communication
• Watch for depression and anxiety (Gordon, 2013, 
pg. 297)
• Due to the rate of progression of the disease, 
patient’s can develop feelings of hopelessness 
and emotional distress about the future (Abdulla 
et al., 2014)
• Monitor weight, calories, and fluids to check 
patient’s nutritional status (Gordon, 2013, pg. 
300)
• Monitor patient’s breathing status
• Determine if mechanical ventilation is an option 
for the patient-less than 5% of patients opt for 
mechanical ventilation, and ones that do can 
progress to locked in syndrome (Gordon, 2013, 
pg. 301). 
Significance of Pathophysiology
Due to the uncertainties in the pathophysiology of amyotrophic lateral sclerosis, 
significance is held in the current knowledge of the genes that could cause ALS, but 
more importantly, significance is held in response to knowing that most cases are 
sporadic.  With 90 to 95% of ALS cases being of spontaneous origin and not 
understanding the genetic makeup thoroughly, physicians must focus on 
presenting symptoms and do the appropriate tests and evaluations to rule out any 
other neurodegenerative diseases (Bellomo & Cichminski, 2015, pg. 48).  With the 
increasing development of genetic prevalence, testing could be done to see if the 
affected individual carries the appropriate genes for further diagnostic evaluation.  
However, with advanced myelin sheath damage and axonal loss, life expectancy is 
not long regardless of whether the patient has the gene correlation or not.  The 
diagnosing physician must be thorough in his/her assessment, and do all the 
appropriate tests to rule out the mimics and give a full diagnosis of ALS, as this 
disease is not one to take lightly. 
(Porth, 2014)
Electromyography is used to diagnose (What is ALS).
